Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-α in whole blood and primary cells from different species

Cellular Physiology and Biochemistry

Volumn 36, Issue 6, 2015, Pages 2237-2249

  Fehr, Sarah ^a   Unger, Anke ^b   Schaeffeler, Elke ^a   Herrmann, Sonja ^a   Laufer, Stefan ^a   Schwab, Matthias ^a,c   Albrecht, Wofgang ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b C a i r Biosciences GmbH   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Kinase TNF ; p38 MAP; Species Differences; Whole Blood

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DORAMAPIMOD; LIPOPOLYSACCHARIDE; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; [4 [4 (4 FLUOROPHENYL) 2 (METHYLSULFONYL) 1H N (TETRAHYDRO 2H PYRAN 4 YL)]]PYRIDIN 2 AMINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC50; LANDRACE PIG; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; SPECIES DIFFERENCE; SPLEEN CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMISTRY; LEWIS RAT; METABOLISM; PIG;

ANIMALIA; MUS; RATTUS; SUIDAE;

ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RATS, INBRED LEW; SPECIES SPECIFICITY; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939625641     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430188     Document Type: Article

References (48)

1. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746
2. Kumar S, Boehm J, Lee JC: p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-726
3. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G: Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54:2745-56.
4. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S: p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002;15:5342-5351.
5. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M: Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-69.
6. Meng Z, Yan C, Deng Q, Dong X, Duan ZM, Gao DF, Niu XL. Oxidized low-density lipoprotein induces inflammatory responses in cultured human mast cells via Toll-like receptor 4. Cell Physiol Biochem 2013;31:842-853.
7. Yang Y, Lian YT, Huang SY, Yang Y, Cheng LX, Liu K: GABA and topiramate inhibit the formation of human macrophage-derived foam cells by modulating cholesterol-metabolism-associated molecules. Cell Physiol Biochem 2014;33:1117-1129.
8. Borst O, Walker B, Mnzer P, Russo A, Schmid E, Faggio C, Bigalke B, Laufer S, Gawaz M, Lang F. Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation. Cell Physiol Biochem 2013;31:914-924.
9. Tang W, Lv Q, Chen XF, Zou JJ, Liu ZM, Shi YQ: CD8(+) T cell-mediated cytotoxicity toward Schwann cells promotes diabetic peripheral neuropathy. Cell Physiol Biochem 2013;32:827-837.
10. Hosokawa Y, Hosokawa I, Shindo S, Ozaki K, Matsuo T: (-)-Epigallocatechin-3-gallate inhibits CC chemokine ligand 11 production in human gingival fibroblasts. Cell Physiol Biochem 2013;31:960-967.
11. Shieh JM, Tsai YJ, Tsou CJ, Wu WB: CXCL1 regulation in human pulmonary epithelial cells by tumor necrosis factor. Cell Physiol Biochem 2014;34:1373-1384.
12. Chen J, Liao MY, Gao XL, Zhong Q, Tang TT, Yu X, Liao YH, Cheng X: IL-17A induces pro-inflammatory cytokines production in macrophages via MAPKinases, NF-κB and AP-1. Cell Physiol Biochem 2013;32:1265-1274.
13. Sweeney SE: The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev Rheumatol 2009;5:475-77.
14. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ: Selective p38a Inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010;53:2345-2353.
15. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP: Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-344.
16. Laufer S, Thuma S, Peifer C, Greim C, Herweh Y, Albrecht A, Dehner F: An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal Biochem 2005;344:135-137.
17. Laufer S, Greim C, Luik S, Ayoub SS, Dehner F: Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity. Inflammopharmacology 2008;16:155-161.
18. Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB: Antiinflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 2009;331:882-895.
19. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmcol Exp Ther 1996;279:1453-1461.
20. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EB, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA: A selective p38α mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006;318:132-141.
21. Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR: Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-619.
22. Zhang X, Huang Y, Navarro MT, Hisoire G, Caulfield JP: A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:1031-1038.
23. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Gahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ: RWJ 67657, a potent, orally active inhibitor of p38 mitogenactivated protein kinase. J Pharmacol Exp Ther 1999;291:680-687.
24. Lee JC, Kassis S, Kumar S, Badger A, Adams JL: p38 mitogen-activated protein kinase inhibitors -mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-397.
25. Yang S, Lukey P, Beerahee M, Hoke F: Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases. Clin Pharmacokinet 2013;52:187-198.
26. Watz H, Barnacle H, Hartley BF, Chan R: Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014;2:63-72.
27. Dewenter M, Vettel C, El-Armouche A: Losmapimod: a novel drug against cardiovascular diseases. Dtsch Med Wochenschr 2013;138:39-42.
28. Ostenfeld T, Krishen A, Lai RY, Bullman J, Baines AJ, Green J, Anand P, Kelly M: Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur J Pain 2013;17:844-857.
29. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-272.
30. Regan J, Capolino A, Cirillo PF, GilmoreT, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, Pargellis CA, SwinamerA, TorcellinC, Tsang M, Moss N: Structure-Activity Relationships of the p38alpha MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J Med Chem 2003;46:4676-4686.
31. Doggrell SA, Christensen AM: Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis? Expert Opin Pharmacother 2010;11:2437-42.
32. Trifilieff A, Keller TH, Press NJ, Howe T, Gedeck P, Beer D, Walker C: CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol 2005;144:1002-1010.
33. Laufer S, Greim C, Bertsche T: An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. Osteoarthritis Cartilage 2002;10:961-967.
34. Carstensen L, Rontved CM, Nielsen JP: Determination of tumor necrosis factor-alpha responsiveness in piglets around weaning using an ex vivo whole blood stimulation assay. Vet Immunol Immunopathol 2005;105:59-66.
35. Laufer S, Greim C, Bertsche T: An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. Osteoarthritis Cartilage 2002;10:961-967.
36. Brown KK, Heimeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ: p38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm 2008;5:22.
37. Ross S, Chen T, Yu V, Tudor Y, Zhang D, Liu L, Tamayo N, Dominguez C, Powers D: High-content screening analysis of the p38 pathway: profiling of structurally related p38a kinase inhibitors using cell-based assays. Assay Drug Dev Technol 2006;4:397-409.
38. Damsgaard CT, Lauritzen L, Calder PC, Kjaer TM, Frokiaer H: Whole-blood culture is a valid low-cost method to measure monocytic cytokines - a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes. J Immunol Methods 2009;340:95-101.
39. Duvigneau JC, Sipos W, Hartl RT, Bayer M, Moldzio R, Stevenson L, Adair B, Gemeiner M: Heparin and EDTA as anticoagulant differentially affect cytokine mRNA level of cultured porcine blood cells. J Immunol Methods 2007;324:38-47.
40. Call DR, Remick DG: Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model. Shock 1998;10:192-197.
41. Heinzelmann M, Bosshart H: Heparin binds to lipopolysaccharide (LPS)-binding protein, facilitates the transfer of LPS to CD14, and enhances LPS-induced activation of peripheral blood monocytes. J Immunol 2005;174:2280-2287.
42. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J: Tumour necrosis factor (TNF) gene poymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-406.
43. Aulock SV, Deininger S, Draing C, Gueinzius K, Dehus O, Hermann C: Gender difference in cytokine secretion on immune stimulation with LPS and LTA. J Interferon Cytokine Res 2006;26:887-892.
44. Dietsch GN, Dipalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST: Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 2006;34:39-51.
45. Foster SJ, McCormick LM, Ntolosi BA, Campbell D: Production of TNFa by LPS-stimulated murine, rat and human blood and its pharmacological modulation. Agents Actions 1993;38:77-79.
46. Cogan DA, Aungst R, Breinlinger EC, Fadra T, Goldberg DR, Hao MH, Kroe R, Moss N, Pargellis C, Qian KC, Swinamer AD: Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2008;18:3251-3255.
47. Gruenbaum LM, Schwartz R, Woska JR, DeLeon RP, Peet GW, Warren TC, Capolino A, Mara L, Morelock MM, Shrutkowski A, Jones JW, Pargellis CA: Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB-796 correlates with the inhibition of p38 signaling. Biochem Pharmacol 2009;77:422-432.
48. Bian H, Zhan J, Wu P, Varty LA, Jia Y, Mayhood T, Hey JA, Wang P: Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 2004;68:2229-2236.